The India Opportunity

IndiPharm: Your Gateway to Clinical Research in India

The total worldwide R&D spending for pharmaceutical and biotech companies (Pharma) in 2007 was $117B, of which 70% represented development costs. This spending is expected to grow at 11% annually and will be $218B in 2013. The CRO market for Phase 1 through 4 trials represented about $7.8B in 2007 and is projected to grow to $17.2B in 2013.

India provides a number of significant advantages for the outsourcing of clinical trials because it offers a large patient population that facilitates faster recruitment, low trial cost per patient, a highly qualified professional medical community, plus global quality hospitals and clinical research facilities. Furthermore, with a highly developed IT and data collection capability and no language barrier, India has become an important destination for clinical trials, and exponential growth is expected in the number of trials conducted there in the near future.